AstraZeneca claims quashed in heartburn drug patent case

An appeals court has ruled in favour of Hanmi Pharmaceuticals in a patent dispute over AstraZeneca's best-selling acid reflux drug Nexium (esomeprazole magnesium).

The US Court of Appeals for the Federal Circuit upheld a lower court's ruling that South Korean drug maker Hanmi did not infringe on a patent held by AstraZeneca for esomeprazole magnesium. AstraZeneca had accused Hanmi of patent infringement as a result of Hanmi's development of an esomeprazole strontium drug, a proton pump inhibitor that is not automatically substitutable for Nexium in pharmacies. However, the court decided that Hanmi's strontium salt does not infringe AstraZeneca’s patent because that patent only applies to the magnesium salt found in Nexium. Nexium had sales of almost $5 billion (£3 billion) in 2010.


Related Content

Pfizer to pay $250m for Nexium

17 August 2012 Business

news image

AstraZeneca has sold rights to an over the counter version of its heartburn tablets

Nanotech patent jungle set to become denser in 2013

17 January 2013 News and Analysis

news image

Is a thicket of patents strangling a nascent industry?

Most Commented

Raman bites into tooth decay

14 April 2014 Research

news image

Mineral distribution signals help discriminate healthy enamel from cavities

The sultan of synthesis

11 April 2014 Feature

news image

Phil Baran is spurring organic chemists to rethink how they make complex compounds, as Mark Peplow discovers